Compare Gilead Sciences, Inc. (GILD) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Mega Cap Growth ETF — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while Vanguard Mega Cap Growth ETF trades at $88.27. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Mega Cap Growth ETF pays none, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | MGK | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $92.06 |
52-Week Low | $108.22 | $70.70 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MGK trades at $88.41, down 0.19% on the day, with a bullish technical signal supported by strong moving average indicators. The ETF maintains a concentrated portfolio in mega-cap growth stocks, particularly technology leaders, with a low expense ratio of 0.05%. Recent corporate actions include a 1:5 stock split executed in April 2026 and an upcoming dividend payment scheduled for June 2026.
MGK's outlook remains positive given its exposure to high-growth technology sectors and cost efficiency, though concentration risk in top holdings presents volatility concerns. The ETF's historical performance has consistently outpaced the S&P 500, but investors should weigh sector concentration against diversification benefits in their portfolio strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
